Is there a role for pembrolizumab beyond progression in urothelial carcinoma?

被引：0
|
作者：
Taguchi, Satoru [1 ]
Kawai, Taketo [2 ]
Nakagawa, Tohru [2 ]
Kume, Haruki [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Urol, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
[2] Teikyo Univ, Sch Med, Dept Urol, Tokyo, Japan
来源：
BJU INTERNATIONAL | 2024年 / 134卷 / 01期
关键词：
D O I：
10.1111/bju.16245
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 44
页数：2
相关论文
共 50 条
  • [41] Chromosome instability and progression in urothelial cell carcinoma of the bladder
    Santos, L
    Pereira, S
    Leite, RP
    Souto, M
    Amaro, T
    Criado, B
    ACTA ONCOLOGICA, 2003, 42 (02) : 169 - 173
  • [42] Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma
    Nozomi Hayakawa
    Eiji Kikuchi
    Shigeaki Suzuki
    Mototsugu Oya
    International Cancer Conference Journal, 2020, 9 : 123 - 126
  • [43] Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
    Tomisaki, Ikko
    Harada, Mirii
    Minato, Akinori
    Nagata, Yujiro
    Kimuro, Rieko
    Higashijima, Katsuyoshi
    Harada, Kenichi
    Fujimoto, Naohiro
    ANTICANCER RESEARCH, 2022, 42 (03) : 1629 - 1634
  • [44] A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
    Fukiishi, Yousuke
    Fukuhara, Hideo
    Kurano, Yoshitaka
    Shugimoto, Hiroki
    Yamashita, Erika
    Karasima, Takashi
    Inoue, Keiji
    IJU CASE REPORTS, 2023, 6 (02) : 128 - 132
  • [45] Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond
    Bianchi, Alberto
    von Deimling, Markus
    Pallauf, Maximilian
    Yanagisawa, Takafumi
    Kawada, Tatsushi
    Mostafaei, Hadi
    Quhal, Fahad
    Laukhtina, Ekaterina
    Rajwa, Pawel
    Majdoub, Muhammad
    Motlagh, Reza Sari
    Pradere, Benjamin
    Karakiewicz, Pierre, I
    Cerruto, Maria Angela
    Antonelli, Alessandro
    Shariat, Shahrokh F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (02) : 177 - 195
  • [46] Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab
    Taguchi, Satoru
    Kawai, Taketo
    Buti, Sebastiano
    Bersanelli, Melissa
    Uemura, Yukari
    Kishitani, Kenjiro
    Miyakawa, Jimpei
    Sugimoto, Kazuma
    Nakamura, Yu
    Niimi, Fusako
    Kaneko, Tomoyuki
    Kamei, Jun
    Obinata, Daisuke
    Yamaguchi, Kenya
    Kakutani, Shigenori
    Kanazawa, Koichiro
    Sugihara, Yuriko
    Tokunaga, Mayuko
    Akiyama, Yoshiyuki
    Yamada, Yuta
    Sato, Yusuke
    Yamada, Daisuke
    Enomoto, Yutaka
    Nishimatsu, Hiroaki
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Nakagawa, Tohru
    Takahashi, Satoru
    Kume, Haruki
    IMMUNOTHERAPY, 2023, 15 (11) : 827 - 837
  • [47] Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report
    Fukushima, Hiroshi
    Fukuda, Shohei
    Moriyama, Shingo
    Uehara, Sho
    Yasuda, Yosuke
    Tanaka, Hajime
    Yoshida, Soichiro
    Yokoyama, Minato
    Matsuoka, Yoh
    Fujii, Yasuhisa
    ANTI-CANCER DRUGS, 2020, 31 (08) : 866 - 871
  • [48] Urothelial Carcinoma: Second-Line Therapy with Pembrolizumab prolongs Survival Time
    Dobler, Gabriele
    Aziz, Atiqullah
    AKTUELLE UROLOGIE, 2019, 50 (01) : 14 - 15
  • [49] Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma
    Kurashina, Ryo
    Ando, Kiyohiro
    Inoue, Masaharu
    Izumi, Keita
    Maruyama, Riko
    Mitani, Kouki
    Takenobu, Hisanori
    Haruta, Masayuki
    Iizuka, Toshihiko
    Kamijo, Takehiko
    Kageyama, Yukio
    ANTICANCER RESEARCH, 2022, 42 (02) : 1131 - 1136
  • [50] Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
    Kamei, Jun
    Yokoyama, Hirotaka
    Niki, Toshiro
    Suda, Ryosuke
    Sugihara, Toru
    Fujisaki, Akira
    Ando, Satoshi
    Iwami, Daiki
    Fujimura, Tetsuya
    IJU CASE REPORTS, 2022, 5 (03) : 199 - 202
12345